New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:40 EDTEXELSummer Street's chief scientific officer holds analyst/industry conference call
Chief Science Officer Classen discusses Exelixis' Cabozantinib for treatment of mestastatic prostate cancer on an Analyst/Industry conference call to be held on March 20 at 10 am.
News For EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
05:24 EDTEXELExelixis announces Genentech files NDA for cobimetinib, vemurafenib combination
Exelixis (EXEL) announced its collaborator Genentech, a member of the Roche Group (RHHBY), has completed the filing of its New Drug Application, or NDA, with the FDA for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year. The NDA is based on data from the coBRIM trial, a phase 3 pivotal trial conducted by Genentech in 495 patients with BRAF V600 mutation-positive unresectable locally advanced or metastatic melanoma.
December 11, 2014
07:28 EDTEXELCBI to hold a summit
2nd Specialty Data Optimization Summit is being held in Philadelphia on December 11.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use